$CORT News

Corcept Therapeutics Discloses Amended Complaint Filed By Former Employee, Will Defend Itself Against Claims

Corcept Therapeutics Announces New Overall Survival Data From Its Pivotal Phase 3 ROSELLA Trial Of Lifyorli Plus Nab-Paclitaxel In An Oral Presentation At The ASCO 2026; Patients Treated With Lifyorli Combined With Nab-Paclitaxel Experienced A 35 Percent Reduction In The Risk Of Death Compared To Patients Treated With Nab-paclitaxel Alone

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $135

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $95

Corcept Therapeutics To Resubmit Its New Drug Application To FDA For Relacorilant To Treat Cushing's Syndrome Patients

UBS Upgrades Corcept Therapeutics to Buy, Raises Price Target to $72

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $75

Piper Sandler Maintains Overweight on Corcept Therapeutics, Raises Price Target to $88

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk

Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript

Corcept Therapeutics (NASDAQ:CORT) Revenue Miss Leads to Q1 Net Loss, But Guidance Upgrade and Lifyorli Launch Signal Strong Momentum

Corcept Therapeutics Q1 2026 Earnings Call Transcript

Corcept Therapeutics Announces Its Phase 2 DAZALS Trial Of Cortisol Modulator Dazucorilant To Treat Amyotrophic Lateral Sclerosis Failed To Meet Primary Endpoint

Corcept Therapeutics Raises FY2026 Sales Guidance from $900.000M-$1.000B to $950.000M-$1.050B vs $941.180M Est

Corcept Therapeutics Q1 EPS $(0.30) Misses $(0.16) Estimate, Sales $164.903M Miss $192.510M Estimate

Corcept Therapeutics To Present Phase 3 ROSELLA Data For Lifyorli In Ovarian Cancer At ASCO 2026

Did Lifyorli’s Landmark Ovarian Cancer Data and NCCN Nod Just Shift Corcept Therapeutics’ (CORT) Investment Narrative?

How The Corcept Therapeutics (CORT) Investment Story Is Shifting After Legal And Regulatory Updates

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer